Aprea Therapeutics (APRE) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
APRE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aprea Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$2.22 |
| 52 Week Low | US$0.55 |
| Beta | 1.56 |
| 1 Month Change | -13.62% |
| 3 Month Change | 15.67% |
| 1 Year Change | -52.84% |
| 3 Year Change | -74.92% |
| 5 Year Change | n/a |
| Change since IPO | -94.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| APRE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.5% | 5.1% | -2.7% |
| 1Y | -52.8% | 36.7% | 18.6% |
Return vs Industry: APRE underperformed the US Biotechs industry which returned 36.7% over the past year.
Return vs Market: APRE underperformed the US Market which returned 18.6% over the past year.
Price Volatility
| APRE volatility | |
|---|---|
| APRE Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APRE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APRE's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Oren Gilad | aprea.com |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc. Fundamentals Summary
| APRE fundamental statistics | |
|---|---|
| Market cap | US$9.78m |
| Earnings (TTM) | -US$11.95m |
| Revenue (TTM) | US$123.30k |
Is APRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APRE income statement (TTM) | |
|---|---|
| Revenue | US$123.30k |
| Cost of Revenue | US$6.17m |
| Gross Profit | -US$6.05m |
| Other Expenses | US$5.91m |
| Earnings | -US$11.95m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | -4,905.14% |
| Net Profit Margin | -9,696.04% |
| Debt/Equity Ratio | 0% |
How did APRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 22:36 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aprea Therapeutics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |